Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03334409 · ClinicalTrials.gov registry record · Phase 2
Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery
A Phase 2 study, sponsored by Academic and Community Cancer Research United.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT03334409 is a Phase 2 study that was terminated before completion, run by Academic and Community Cancer Research United. The registered enrollment target is 5 participants.
The verdict
NCT03334409, a Phase 2 study, was terminated before completion, sponsored by Academic and Community Cancer Research United.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well pazopanib hydrochloride with or without ascorbic acid work in treating patients with kidney cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Ascorbic acid may help pazopanib hydrochloride stop tumor growth and improve treatment survival. Giving pazopanib hydrochloride and ascorbic acid may work better in treating patients with kidney cancer.
Interventions
- DRUG Pazopanib Hydrochloride
- DRUG Ascorbic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-02-16 |
| Est. Completion | 2021-03-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03334409
The ClinicalTrials.gov registry entry for NCT03334409 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Academic and Community Cancer Research United, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pazopanib Hydrochloride is the first listed.
NCT03334409 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03334409 about?
NCT03334409 is a clinical study titled "Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery". This randomized phase II trial studies how well pazopanib hydrochloride with or without ascorbic acid work in treating patients with kidney cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery. Pazopanib hydrochloride may stop the growth of tumor cells by b...
What is the current status of trial NCT03334409?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2018-02-16. Estimated completion is 2021-03-13.
What interventions are being tested in trial NCT03334409?
The interventions under investigation include: Pazopanib Hydrochloride (DRUG), Ascorbic Acid (DRUG).
Who is sponsoring clinical trial NCT03334409?
This trial is sponsored by Academic and Community Cancer Research United, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.